A breakthrough in life-saving medical technology has arrived. The U.S. Food and Drug Administration (FDA) has officially ...

Silver Spring, Md Thursday, December 26, 2024, 11:00 Hrs [IST] ...

The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed ...

Humacyte's Symvess earns FDA approval as a first-in-class bioengineered vascular solution for urgent arterial injury repair ...

A Durham company secured federal approval for its bioengineered tissue, which could become a revolutionary treatment for ...

The U.S. Food and Drug Administration approved Symvess, the first acellular tissue engineered vessel indicated for use in ...

The first acellular tissue engineered vessel for adults with vascular trauma in a bodily extremity has been approved by the U.S. FDA. Symvess, which comes from regenerative tissue developer Humacyte ...

There is a considerable clinical need for alternatives to the autologous vein and artery tissues used for vascular reconstructive surgeries such as CABG, lower limb bypass, arteriovenous shunts ...

SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...

Humacyte Inc. shares surged over 70% early on Friday, reaching their highest levels in over a month amid skyrocketing retail ...

has granted a full approval for SYMVESS (acellular tissue engineered vessel-tyod) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to ...